Super Group (SGHC) Limited Ordinary Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Super Group (SGHC) Limited Ordinary Shares trades at $11.33 (market cap $5.86B), while State Street SPDR S&P Biotech ETF trades at $154.01 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.73% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| SGHC | XBI | |
|---|---|---|
Market Cap | $5.86B | $10.11B |
Volume | 1,905,788 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $15.59 | $169.55 |
52-Week Low | $8.52 | $104.99 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $5.41B | — |
Dividend Yield | 1.73% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →